Iovance Biotherapeutics (NASDAQ:IOVA) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Iovance Biotherapeutics (NASDAQ:IOVA) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.04, FiscalAI reports. The firm had revenue of $121.47 million during the quarter, compared to analysts’ expectations of $115.98 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%. The business’s revenue was up 64.8% on a year-over-year basis.

Here are the key takeaways from Iovance Biotherapeutics’ conference call:

• Iovance reported record third-quarter revenue of approximately $122 million, up 80% year over year, including about $102 million from AMTAGVI; it reaffirmed 2026 revenue guidance of $410 million–$420 million. The company has treated more than 1,000 commercial patients and expects at least 110 authorized treatment centers by year-end.
• Gross margin reached a record 60%, operating expenses were managed tightly, and Iovance ended the quarter with approximately $382 million in cash, which it expects to fund operations well into 2029. Management said it is moving toward profitability but did not provide a timeline.
• In previously treated non-squamous metastatic lung cancer, lifileucel showed a 24.6% response rate among 69 patients; a biomarker-enriched subgroup had a 59.1% response rate. Iovance plans an sBLA submission in 2027 and is starting a prospective biomarker-selected study, though the findings remain investigational.
• Updated soft tissue sarcoma results showed a 55.6% response rate in five of nine patients with UPS or DDLPS, including two responses ongoing beyond a year. The registrational SARATOGA trial is enrolling, with submissions planned for 2028 or 2029.
• In a phase II frontline melanoma cohort, lifileucel plus pembrolizumab produced a 62.5% response rate, including complete responses in 29.2% of patients; median overall survival had not been reached after more than four years of follow-up. The phase III TILVANCE-301 trial is enrolling to support a potential frontline approval.

Iovance Biotherapeutics Trading Up 1.6%

Shares of IOVA opened at $8.17 on Tuesday. The stock has a market cap of $3.70 billion, a PE ratio of -15.42 and a beta of 0.88. Iovance Biotherapeutics has a 1 year low of $2.08 and a 1 year high of $15.37. The stock has a 50 day simple moving average of $11.38 and a 200-day simple moving average of $6.00.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. UBS Group lifted their price target on Iovance Biotherapeutics from $7.00 to $8.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 3rd. HC Wainwright increased their price objective on Iovance Biotherapeutics from $9.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, September 29th. Citizens Jmp raised their price objective on shares of Iovance Biotherapeutics from $8.00 to $12.00 and gave the stock a “market outperform” rating in a research note on Friday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research report on Tuesday, September 29th. Finally, Robert W. Baird upped their target price on shares of Iovance Biotherapeutics from $6.00 to $11.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $13.80.

About Iovance Biotherapeutics

Iovance Biotherapeutics is a biotechnology company focused on developing and commercializing personalized cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, which are expanded in a laboratory and returned to the patient.

The company’s lead product, Amtagvi (lifileucel), is a TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma previously treated with specified therapies.